Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, and Acute Lymphoblastic Leukemia research.
Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting– a retrospective study
Loss of p53 enhances LMO2 induced transdifferentiation of B-cells to T-cell acute lymphoblastic leukemia
Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights
Gilteritinib with or without venetoclax for relapsed/refractory <i>FLT3</i>‐mutated acute myeloid leukaemia
Post‐Relapse Outcomes of Older Patients With <i>NPM1</i>‐Mutated <scp>AML</scp> Are Favorable With Allo Transplant in Second Remission
Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature
For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious
<i>DNMT3A, TET2, and ASXL1</i> (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms
Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study
Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients
Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
Monitoring Minimal Residual Disease in <b><i>RUNX1</i></b>-Mutated Acute Myeloid Leukemia
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma
Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition